Source comparison
IGF-1 LR3 vs MK-677: Which Is Better? | Real Peptides
A 2018 study published in the Journal of Clinical Endocrinology & Metabolism found that MK-677 increased mean 24-hour growth hormone levels by 97% and IGF-1 levels by 60% in healthy adults—but the growth hormone pulses themselves remained physiologically patte
This comparison does not assign a generated winner or score.
- A 2018 study published in the Journal of Clinical Endocrinology & Metabolism found that MK-677 increased mean 24-hour growth hormone levels by 97% and IGF-1 levels by 60% in healthy adults—but the growth hormone pulses themselves remained physiologically patterned, not sustained. That distinction matters more than most comparison guides acknowledge. IGF-1 LR3, by contrast, delivers supraphysiological IGF-1 receptor activation independent of endogenous growth hormone secretion, bypassing the negative feedback loop that limits MK-677's long-term efficacy.
- Our team at Real Peptides has supplied both compounds to research institutions conducting head-to-head comparisons. The gap between doing this comparison right and doing it wrong comes down to understanding receptor pharmacology—not just reading product descriptions.
- Which compound produces more pronounced anabolic effects: IGF-1 LR3 or MK-677?
- IGF-1 LR3 produces more direct anabolic signaling because it binds IGF-1 receptors with similar affinity to native IGF-1 but remains active 2–3 times longer due to reduced binding to IGFBPs (insulin-like growth factor binding proteins). MK-677 increases endogenous IGF-1 indirectly through growth hormone elevation, meaning its anabolic potential is limited by the subject's intact hypothalamic-pituitary axis and existing IGF-1 production capacity. Research models typically observe greater acute protein synthesis markers with IGF-1 LR3, while MK-677 demonstrates more sustained but moderate IGF-1 elevation over weeks.
- IGF-1 LR3 is not 'MK-677 on steroids'—it's a fundamentally different tool. MK-677 mimics ghrelin to trigger pulsatile GH release. IGF-1 LR3 is the end-effector molecule itself, modified to resist degradation. This article covers the specific receptor mechanisms at work, the half-life and dosing implications that determine experimental outcomes, and exactly when one compound's pharmacology makes it better suited than the other for specific research protocols.